VASC

INTEGRATING SCIENCE AND GUIDELINES INTO A PRACTICAL CALL TO ACTION FOR CARDIOVASCULAR SPECIALISTS: AN INTERACTIVE CASE-BASED DISCUSSION

Presenter(s)

• 

  Ronald Goldenberg, MD, FRCPC, FACE

  Consultant Endocrinologist
• 

  G.B. John Mancini, MD, FRCPC, FACP, FACC

  Cardiologist, Cardiac Computed Tomographic Angiography Program
  University of British Columbia
• 

  Eileen O'Meara, MD, FRCPC

  Head, Outpatient Clinics
  Université de Montréal

Learning Objectives

At the conclusion of this session, participants will be able to:

• to interpret how the CVOT data may be translated to people with type 2 diabetes, with and without ASCVD;
• to infer how the guidelines may change to accommodate the use of SGLT2 inhibitors beyond type 2 diabetes; and
• to determine how to optimize lipid-lowering strategies so as to lower residual risk in people with type 2 diabetes.